New Allergy Vaccine On Track For Pivotal Trial Phase

grass-pollen-vaccine

Bombay is a privately-owned medical company that is located in Austria. It has developed a grass pollen vaccine, which is known as BM32. They recently completed the second phase of the study. The immunotherapeutics specialists stated that the second phase of the study showed that subjects who received five monthly injections of BM32 noticed a significant improvement in their symptoms.

The first phase of the study also showed that BM32 is safe. Most of the subjects only experienced mild to moderate side effects. The subjects also recovered quickly from the side effects that they experienced.

There were 70 patients in the study. All of them suffered from grass pollen sensitivity. The results of the study showed that the subjects were less sensitive to the pollen. All of them were given subcutaneous injections for two months. This technology also eliminated the need for other allergy treatments.

Rainer Henning is the chief executive of Biomay. He stated that the second phase of the treatment was very successful. He stated that they were able to demonstrate that BM32 can successfully alleviate allergy symptoms. The third phase of the trial will be starting soon. They are hoping that the grass pollen vaccine will be available on the market by the year 2021.

Rainer stated that he was encouraged by seeing the results of the study. He stated that the results validated the hypothesis. They noticed that the grass pollen vaccine helped the body produce protective antibodies. It also helped eliminate the need for multiple injections. The technology also allowed people to get results with minimal side effects.

[blog_slider title=”” count=”6″ category=”” category_multi=”” more=”0″ style=”” navigation=””]

About the Grass Pollen Vaccine

BM32 is a vaccine that was invented by Prof. Rudolf Valenta at the Medical University of Vienna. It is designed to protect patients from the side effects of grass pollen exposure. The researchers have stated that people who get three or four injections of BM32 per year are able to have long-term results.

Allergies and Immunotherapy

Allergies are a public health problem that is becoming more common. It is estimated that 25 percent of the world’s population suffers from allergies. Half of these patients suffer from a grass pollen allergy. Many patients have trouble completing their activities of daily living because of this condition. This medical condition develops when the immune system overacts to a harmless substance.

No one knows exactly why some people develop allergies. However, some medical experts believe that allergies develop when people are exposed to an allergen during the same time they are fighting off a virus. When the immune system is fighting off an illness, one may develop an allergic response to something else.

Many people believe that people develop allergies because they are not adequately exposed to bacteria and viruses during their childhood. Clean water, antibacterial soap and pasteurized milk are some of the main reasons that children today are not exposed to as many bacteria and viruses. As a result, the immune system does not have as much opportunity to distinguish between harmless and dangerous pathogens.

Immunotherapy is also known as desensitization treatment. It not only alleviates the symptoms of the condition, but it can also change the course of the disease. Immunotherapy has been around for over 100 years.

Learn more about Vaccine News.

GET HELP NOW!

w

You Only Have Three Years To File Your Claim

The first step in helping yourself or a loved one after a serious vaccine related injury is to contact us for a free review of your case.

Recent Posts